The use of drotrecogin alfa (activated) in solid organ transplant patients: A case series

Transplant Infectious Disease

Volumn 11, Issue 3, 2009, Pages 269-276

  Berkman, S ^a   Weimert, N A ^a,c   Taber, D J ^a   Baillie, G M ^a   Lin, A ^b   Baliga, P ^b   Chavin, K D ^b  

^a Department of Pharmacy Services ^*  (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Drotrecogin alfa (activated); Protein C; Transplantation; Xigris

Indexed keywords

DROTRECOGIN; HYPERTENSIVE FACTOR;

ABDOMINAL INFECTION; ADULT; AGED; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; BLOODSTREAM INFECTION; CLINICAL ARTICLE; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY INFECTION; LUNG INFECTION; MALE; MEDICAL RECORD REVIEW; MORTALITY; MULTIPLE ORGAN FAILURE; ORGAN TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEPSIS; SIDE EFFECT;

ADULT; AGED; APACHE; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; TREATMENT OUTCOME;

EID: 67149120800     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2009.00393.x     Document Type: Article

References (19)

1. Kalil AC, Dakroub H, Freifeld AG. Sepsis and solid organ transplantation. Curr Drug Targets 2007 8 : 533 541. (Pubitemid 46672621)
2. Wagener MM, Yu VL. Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors and outcomes. Am J Infect Control 1992 20 : 239 247.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001 29 : 1303 1310. (Pubitemid 32641789)
4. Boucher B, Olsen KM. Drotrecogin alfa (activated) in the management of sepsis. Pharmacotherapy 2002 22 : 167s 168s. (Pubitemid 35429939)
5. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999 340 : 207 214. (Pubitemid 29063218)
6. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 334 : 699 709. (Pubitemid 32204987)
7. Morris PE, Light RB, Garber GE. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated). Am J Surg 2003 184 : 19s 24s.
8. Browne E, Cressey DM, Agarwal K, Cosgrove JF. The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant. Anaesthesia 2007 62 : 282 285. (Pubitemid 46680650)
9. Feltracco P, Bortolato A, Rizzi S, et al. Activated recombinant protein C in septic shock early after liver transplantation: a case report. Transplant Proc 2008 40 : 2070 2072.
10. Kulkarni S, Naureckas E, Cronin DC II. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. Transplantation 2003 75 : 899 901. (Pubitemid 36373467)
11. Al-Sabah S, Goldberg P, Qureshi ST. Pasteurella multocida septic shock following liver transplantation treated with drotrecogin alfa (activated). Transpl Infect Dis 2007 9 : 233 236. (Pubitemid 47231201)
12. Grochowiecki T, Nazarewski S, Meszaros J, et al. Use of drotrecogin alpha (recombinant human activated protein C, rhAPC) in the treatment of severe sepsis induced by graft pancreatitis after simultaneous pancreas and kidney transplantation: a case report. Transplant Proc 2006 38 : 276 279. (Pubitemid 43303658)
13. Feltracco P, Rea F, Ori C. Drotrecogin alfa (activated) in septic shock after lung transplant. J Heart Lung Transplant 2008 27 : 815.
14. Daniels TL, Dummer JS, Bernard GR, Milstone AP. A case series of drotrecogin alfa (activated) in lung transplant recipients. Transplantation 2006 81 : 1739 1742. (Pubitemid 43948309)
15. Drotrecogin alfa (activated) product information. Available at (accessed December 24, 2008).
16. Schein RM, Kinasewitz GT. Risk-benefit analysis for drotrecogin alfa (activated). Am J Surg 2002 184 : 25s 38s. (Pubitemid 36071433)
17. Ely EW, Laterre PF, Angus DC, et al PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003 31 : 12 19. (Pubitemid 36151143)
18. Angus DC, Laterre PF, Helterbrand J, et al PROWESS Investigators. The effects of drotrecogin alfa (activated) on long-term survival after severe sepsis. Chest 2004 32 : 2199 2206. (Pubitemid 39491798)
19. Angus DC, Linde-Zwirble WT, Clermont G, et al PROWESS Investigators. l. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003 31 : 1 11. (Pubitemid 36151142)